GlassScriptPhysician profile
Greg Vaughan Manson
NPI 1689882961
$7,717.35
in general payments reported to CMS, 2019-2025
46 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,020 · 2020: $1,367 · 2021: $2,634 · 2022: $352 · 2023: $74.08 · 2024: $129 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275 · Education: $69.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.17 |
| Education | $69.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $869.02 | 2019-2022 | |
| Amgen INC. | $765.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $618.96 | 2019-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $604.95 | 2019-2021 | |
| Daiichi Sankyo INC. | $477.57 | 2019-2023 | Injectafer |
| Genentech USA, INC. | $469.82 | 2019-2025 | Polivy |
| Merck Sharp & Dohme LLC | $455.71 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $236.86 | 2019-2022 | |
| Astellas Pharma US INC | $214.54 | 2019-2021 | |
| Seagen INC. | $212.61 | 2019-2022 | |
| Incyte Corporation | $211.47 | 2019-2022 | |
| Lilly USA, LLC | $209.67 | 2019-2021 | |
| Eisai INC. | $204.08 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $189.74 | 2019-2021 | |
| Celgene Corporation | $182.59 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Manson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.